Effects of Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) Formulated in Alum (GAD-Alum) on the Progression of Type 1 Diabetes in New Onset Subjects.

Trial Profile

Effects of Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) Formulated in Alum (GAD-Alum) on the Progression of Type 1 Diabetes in New Onset Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2016

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jun 2011 Follow up is continuing for a further 12 months.
    • 28 Jun 2011 Results were presented at the 71st Scientific Sessions of the American Diabetes Association (ADA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top